Advertisement
BDX vs MMSI
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. Merit Medical Systems (MMSI) Stock Comparison
Key Takeaways
- BDX is a large-cap global medical technology giant with approximately $21.8 billion in annual revenue, while MMSI is a mid-cap specialist generating roughly $1.5 billion, focused on single-use interventional devices.
- BDX has been navigating a major strategic transformation, including the planned separation of its Biosciences and Diagnostic Solutions business, while MMSI has been executing a disciplined organic and acquisitive growth strategy.
- MMSI has demonstrated stronger recent revenue momentum, with double-digit constant-currency growth and record gross margins, whereas BDX faces near-term headwinds from China, tariffs, and vaccine revenue declines.
- BDX offers a dividend yield of approximately 2.66% and carries a very low beta, appealing to income-oriented and defensive investors; MMSI does not pay a dividend and carries higher growth expectations.
- Analyst sentiment leans cautiously optimistic on BDX with a consensus "Moderate Buy," while MMSI has garnered Buy ratings with double-digit upside targets from several research firms.
- Both stocks operate in the medical technology space, yet they differ considerably in scale, growth profile, and risk-reward dynamics, making this a classic large-cap stability versus mid-cap growth comparison.
Introduction
Investors evaluating medical technology stocks often face a choice between established industry leaders and agile mid-cap growth names. BDX, representing Becton, Dickinson and Company, and MMSI, representing Merit Medical Systems, embody this contrast. Both companies operate within the healthcare sector and supply essential devices to hospitals and clinicians worldwide, yet their scale, growth trajectories, and market positioning differ substantially. This comparison examines how these two stocks stack up across business fundamentals, recent performance, and forward-looking catalysts. Whether you are a defensive investor seeking stability and income or a growth-oriented investor drawn to expanding mid-cap franchises, understanding the trade-offs between BDX and MMSI can help clarify which narrative aligns with your investment perspective.
BDX Overview and Recent Performance
Becton, Dickinson and Company (BDX) is one of the world's largest medical technology firms, with a market capitalization of approximately $43 billion and operations spanning three core segments: BD Medical, BD Life Sciences, and BD Interventional. The company manufactures and sells a vast portfolio of medical supplies, devices, laboratory equipment, and diagnostic products used across hospitals, research laboratories, and pharmaceutical settings globally.
In recent months, BDX has traded in a range between roughly $127 and $187 per share, well below its multi-year highs. The stock has been pressured by a combination of factors including headwinds in China related to volume-based procurement, declining vaccine-related revenue in its Pharmaceutical Systems unit, and tariff-related cost pressures. For its fiscal year 2025, which ended September 30, 2025, BDX reported total revenue of $21.8 billion, representing 8.2% reported growth and 2.9% organic growth. Adjusted diluted earnings per share (EPS) came in at $14.40, reflecting 9.6% growth year-over-year.
A defining strategic development for BDX is the planned combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, structured as a tax-efficient Reverse Morris Trust transaction. This move is designed to create a more focused "New BD" centered on higher-growth MedTech markets. The transaction is expected to close around the end of the first quarter of calendar 2026. Management has guided for fiscal 2026 adjusted EPS in the range of $14.75 to $15.05, with low single-digit revenue growth. The company continues to return capital to shareholders, having distributed $2.2 billion in fiscal 2025 through dividends and share repurchases.
MMSI Overview and Recent Performance
Merit Medical Systems (MMSI) is a global manufacturer and marketer of single-use medical devices for interventional, diagnostic, and therapeutic procedures, primarily serving cardiology, radiology, oncology, and endoscopy markets. With a market capitalization of approximately $5 billion, MMSI is significantly smaller than BDX but has been delivering robust growth through a combination of organic expansion and strategic acquisitions.
Recent trading activity has placed MMSI shares in a range between approximately $78 and $111 over the past 52 weeks, reflecting some volatility but also resilience. The company has consistently exceeded consensus expectations in recent quarters. For the full fiscal year 2025, MMSI reported total revenue of $1.516 billion, representing 12% reported growth and constant-currency organic growth of approximately 6.8%. Non-GAAP EPS reached $3.83, and the company generated free cash flow of more than $215 million, up 16% year-over-year.
Notable developments in recent months include the appointment of Martha G. Aronson as President and CEO, effective October 2025, succeeding longtime founder-CEO Fred Lampropoulos, who remains Chairman. MMSI has also been integrating acquisitions such as Biolife (StatSeal and WoundSeal hemostatic devices) and advancing its Continued Growth Initiatives (CGI) program, which targets an organic revenue compound annual growth rate (CAGR) of 5% to 7% and non-GAAP operating margins of 20% to 22% through December 2026. Looking ahead to fiscal 2026, management has guided for revenue of $1.61 billion to $1.63 billion and non-GAAP EPS of $4.01 to $4.15, implying continued mid-to-high single-digit growth despite tariff and macroeconomic uncertainties.
Trending AI Robots
For traders seeking a data-driven edge in stock selection, Tickeron's Trending AI Robots page offers a curated look at the platform's most promising AI-powered trading bots. Tickeron hosts hundreds of AI Trading Bots that actively trade thousands of different tickers across diverse market conditions, but only a select group earns a place in the Trending AI Robots section. These bots employ varied trading styles and strategies, from swing trading and trend following to mean reversion and breakout detection, each with its own performance statistics, timeframe preferences, and roster of traded tickers. Traders can review metrics such as annualized returns, win rates, maximum drawdowns, and trade frequency to find bots that align with their risk tolerance and trading objectives. Whether you are evaluating BDX and MMSI or exploring opportunities across the broader market, visiting the Trending AI Robots page can help you identify algorithmically driven strategies optimized for current conditions.
Head-to-Head Comparison
When comparing BDX and MMSI side by side, several structural differences emerge. BDX operates at a vastly larger scale, with revenue roughly 14 times that of MMSI, and benefits from deep diversification across medical, life sciences, and interventional segments. Its massive installed base of products — from BD Pyxis medication dispensing systems to BD Vacutainer blood collection devices — creates meaningful switching costs and recurring revenue streams. However, this scale also means BDX faces slower organic growth, with recent organic revenue expansion in the low single digits. MMSI, by contrast, has been growing its top line at a double-digit pace on a constant-currency basis, fueled by product launches in cardiac intervention, peripheral intervention, and endoscopy, as well as contributions from acquisitions.
On profitability, both companies have been expanding non-GAAP margins, but the trajectories differ. BDX posted an adjusted operating margin of 25.0% in fiscal 2025, significantly higher than MMSI's 20.3%, reflecting the efficiency advantages of scale. That said, MMSI's margins have been climbing more rapidly — up 131 basis points year-over-year — and the company's CGI program explicitly targets further expansion. BDX, meanwhile, faces margin headwinds from tariffs, China, and the integration costs associated with its pending transaction with Waters Corporation.
Risk profiles also diverge. BDX's low beta of approximately 0.21 to 0.27 indicates the stock is far less volatile than the broader market, making it a relatively defensive holding. Its dividend yield of roughly 2.66% adds an income component. MMSI, with its smaller market cap and higher growth expectations, exhibits greater volatility and carries execution risk tied to acquisition integration and new product launches such as the WRAPSODY drug-coated balloon. Both companies face shared macro risks, including potential changes to U.S. trade policy, Medicare reimbursement dynamics, and hospital capital spending cycles. Yet MMSI's concentrated exposure to interventional cardiology and radiology markets makes it more sensitive to procedural volume trends, while BDX's breadth provides some insulation.
Tickeron AI Verdict
Based on observable trends, relative positioning, and the nature of each company's current catalysts, Tickeron's AI-driven analysis would likely express a conditional preference for MMSI over BDX in the current market environment, particularly for momentum-oriented and growth-focused strategies. MMSI's consistent pattern of beating consensus estimates, its expanding margins, strong free cash flow generation, and the tangible financial targets embedded in its CGI program present a cleaner, more upward-trending narrative. The company's mid-cap profile also leaves room for multiple expansion as it executes. BDX, while fundamentally sound and attractively valued on a forward earnings basis, faces a more complex near-term picture — the Waters Corporation transaction, while strategically promising long-term, introduces execution uncertainty, and headwinds from tariffs, China, and moderating vaccine revenue may weigh on sentiment. For risk-averse, income-focused investors, BDX's low volatility and dividend yield remain compelling, but the AI's probabilistic framework would likely favor the stock with more consistent positive earnings momentum and fewer transitional uncertainties — and at present, that tilt points toward MMSI.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a StrongBuy and MMSI is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 1 FA rating(s) are green whileMMSI’s FA Score has 0 green FA rating(s).
- BDX’s FA Score: 1 green, 4 red.
- MMSI’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 4 TA indicator(s) are bullish while MMSI’s TA Score has 4 bullish TA indicator(s).
- BDX’s TA Score: 4 bullish, 4 bearish.
- MMSI’s TA Score: 4 bullish, 4 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а +0.42% price change this week, while MMSI (@Pharmaceuticals: Other) price change was +2.61% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.39%. For the same industry, the average monthly price growth was +2.13%, and the average quarterly price growth was -10.16%.
Reported Earning Dates
BDX is expected to report earnings on Aug 06, 2026.
MMSI is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.39% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BDX | MMSI | BDX / MMSI | |
| Capitalization | 42.6B | 4.48B | 950% |
| EBITDA | 4.97B | 349M | 1,424% |
| Gain YTD | 2.586 | -14.715 | -18% |
| P/E Ratio | 26.96 | 32.39 | 83% |
| Revenue | 22.2B | 1.54B | 1,440% |
| Total Cash | N/A | 488M | - |
| Total Debt | 17.3B | 822M | 2,105% |
BDX | MMSI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 82 | |
SMR RATING 1..100 | 87 | 75 | |
PRICE GROWTH RATING 1..100 | 48 | 51 | |
P/E GROWTH RATING 1..100 | 74 | 74 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (7) in the Medical Specialties industry is somewhat better than the same rating for MMSI (72). This means that BDX’s stock grew somewhat faster than MMSI’s over the last 12 months.
MMSI's Profit vs Risk Rating (82) in the Medical Specialties industry is in the same range as BDX (100). This means that MMSI’s stock grew similarly to BDX’s over the last 12 months.
MMSI's SMR Rating (75) in the Medical Specialties industry is in the same range as BDX (87). This means that MMSI’s stock grew similarly to BDX’s over the last 12 months.
BDX's Price Growth Rating (48) in the Medical Specialties industry is in the same range as MMSI (51). This means that BDX’s stock grew similarly to MMSI’s over the last 12 months.
BDX's P/E Growth Rating (74) in the Medical Specialties industry is in the same range as MMSI (74). This means that BDX’s stock grew similarly to MMSI’s over the last 12 months.
| BDX | MMSI | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 70% |
| Stochastic ODDS (%) | 2 days ago 48% | 2 days ago 69% |
| Momentum ODDS (%) | 2 days ago 49% | N/A |
| MACD ODDS (%) | 2 days ago 47% | N/A |
| TrendWeek ODDS (%) | 2 days ago 46% | 2 days ago 59% |
| TrendMonth ODDS (%) | 2 days ago 49% | 2 days ago 55% |
| Advances ODDS (%) | 6 days ago 43% | 6 days ago 65% |
| Declines ODDS (%) | 2 days ago 43% | 8 days ago 57% |
| BollingerBands ODDS (%) | 2 days ago 61% | 2 days ago 50% |
| Aroon ODDS (%) | N/A | 2 days ago 48% |
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | -2.33% | ||
| COO - BDX | 54% Loosely correlated | -0.17% | ||
| TMO - BDX | 50% Loosely correlated | -1.17% | ||
| BAX - BDX | 49% Loosely correlated | -2.39% | ||
| CNMD - BDX | 48% Loosely correlated | +0.58% | ||
| MMSI - BDX | 45% Loosely correlated | +1.59% | ||
More | ||||
MMSI and
Correlation & Price change
A.I.dvisor indicates that over the last year, MMSI has been loosely correlated with BSX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MMSI jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To MMSI | 1D Price Change % | ||
|---|---|---|---|---|
| MMSI | 100% | +1.59% | ||
| BSX - MMSI | 56% Loosely correlated | -0.59% | ||
| SYK - MMSI | 50% Loosely correlated | -0.23% | ||
| ICUI - MMSI | 47% Loosely correlated | -0.11% | ||
| BDX - MMSI | 44% Loosely correlated | -2.33% | ||
| A - MMSI | 43% Loosely correlated | -0.91% | ||
More | ||||